This article summarizes the morbidity and mortality associated with COPD and was created from a presentation given at the 130th AAIM Annual Meeting. The author reviews what most medical directors already know about COPD, but with particular attention paid to the Pulmonary Function Tests dealing with spirometry. Underwriters and medical directors need to understand the three basic measurements of spirometry (FVC, FEV1, and FEF25-75), as well as the significance of the FEV1/FVC ratio, in establishing an applicant as having an obstructive or restrictive impairment.
Skip Nav Destination
MORTALITY PRESENTATION| April 19 2023
Morbidity and Mortality Associated with Chronic Obstructive Pulmonary Disease (COPD)
J Insur Med (2023) 49 (4): 230–243.
Rodney C Richie; Morbidity and Mortality Associated with Chronic Obstructive Pulmonary Disease (COPD). J Insur Med 1 January 2023; 49 (4): 230–243. doi: https://doi.org/10.17849/insm-49-04-230-243.1
Download citation file:
Citing articles via
Prevalence of Antibodies to COVID-19 Due to Infection or Vaccination in US Adults
Robert L Stout, PhD, Steven J Rigatti, MD, DBIM, DABFM
Correlates and Predictors of NT-proBNP in Life Insurance Applicants
Steven J. Rigatti, MD, DBIM, DABFM, Robert Stout, PhD
Methods for Inclusive Underwriting of Breast Cancer Risk with Machine Learning and Innovative Algorithms
Manuel Plisson, PhD, Antoine Moll, MSc, Valentine Sarrazin, MSc, Denis Charles, MSc, Thibault Antoine, MSc, Razvan Ionescu, MSc, Odile Koehren, BSc, Eric Raymond, MD, PhD
Non-Hodgkin Lymphoma – Nodal and Extranodal: 20-Year Comparative Mortality, Survival & Biologic Behavior Analysis by Age, Sex, Race, Stage, Cell Morphology/Histology, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 384,651 Total NHL Cases Including 261,144 Nodal and 123,507 Extranodal Cases for Diagnosis Years 1975-2016: (SEER*Stat 8.3.6)
Anthony F. Milano, MD, MPH, MA, DBIM